Immunome (IMNM) moved back into focus after the European Medicines Agency validated its Marketing Authorization Application for varegacestat and new Phase 3 data were shared at the 2026 ESMO Congress.
Against that backdrop of clinical and regulatory progress, Immunome’s recent trading has been choppy, with the share price falling 3.89% on the day to US$19.52 but still posting a 6.73% 7 day share price return and a 25.94% total shareholder return over the past year. This suggests that momentum has cooled in the short term even as the longer term payoff for holders has remained much stronger.
Scan beyond Immunome and spot other oncology-focused plays that may benefit from late-stage trial progress and regulatory catalysts with the curated 38 healthcare AI stocks.
Immunome has just dropped back after strong clinical headlines, which leaves you choosing between treating this as an early entry or waiting for a deeper pullback. How does the current price compare with the fundamentals?
Most Popular Narrative: 46% Undervalued
On the most followed view, Immunome’s fair value sits at $36.31, well above the last close of $19.52, which puts a lot of weight on its future pipeline delivering.
FDA acceptance of Immunome’s NDA for varegacestat in desmoid tumors with an April 28, 2027 PDUFA date sets up a potential first commercial product and a new revenue line that could shift the company’s earnings profile from primarily R&D expense to a mix of product sales and development spending.
See why 1 investors see Immunome as 46% undervalued.
Result: Fair Value of $36.31 (UNDERVALUED)
Still, the bullish Immunome story depends heavily on varegacestat clearing FDA review without major label limits and on desmoid specialists actually shifting to broader systemic treatment.
Find out about the key risks to this Immunome narrative.
Another View: What Multiples Say About Immunome
That 46% discount to fair value leans heavily on future cash flows. Look at simple balance sheet pricing and the picture shifts. Immunome trades on a P/B of 4.4x, compared with 1.8x for the wider US Biotechs group and 3.4x across peers, which points to a richer tag. Is that premium a cushion or a risk if sentiment turns?
To stress test that richer P/B against earnings power and balance sheet strength, take a closer look at how the market is weighing Immunome’s current ratio against where a fair ratio could settle over time with the See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
Sentiment around Immunome is split, with meaningful concerns sitting alongside genuine optimism about what could come next. Move quickly and review the underlying numbers and narrative for yourself through the 3 key rewards and 3 important warning signs.
Ready To Find More Ideas Beyond Immunome?
If Immunome has caught your attention, do not stop at a single ticker. Broaden your watchlist now and give yourself more options before the next catalyst hits.
- Hunt for potential mispricings by scanning a curated 34 high quality undervalued stocks that filters for quality first, then price.
- Target consistency and income by reviewing a focused 5 dividend fortresses that screens for higher yields with an eye on resilience.
- Zero in on financial strength by working through a practical list of solid balance sheet and fundamentals (25 results) that highlights sturdier balance sheets and fundamentals.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com